RU94040856A - Вакцина для перорального введения - Google Patents

Вакцина для перорального введения

Info

Publication number
RU94040856A
RU94040856A RU94040856/14A RU94040856A RU94040856A RU 94040856 A RU94040856 A RU 94040856A RU 94040856/14 A RU94040856/14 A RU 94040856/14A RU 94040856 A RU94040856 A RU 94040856A RU 94040856 A RU94040856 A RU 94040856A
Authority
RU
Russia
Prior art keywords
vaccine
antigens
oral
oral administration
lipid
Prior art date
Application number
RU94040856/14A
Other languages
English (en)
Inventor
Тсутия Сейси
Jp]
Арамаки Юкихико
Хара Тосифуми
Кикути Хироси
Яти Кието
Икеути Тохру
Original Assignee
Дайити Фармасьютикал Ко.
Дайити Фармасьютикал Ко., Лтд.
Лтд. (Jp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Дайити Фармасьютикал Ко., Лтд., Лтд. (Jp) filed Critical Дайити Фармасьютикал Ко.
Publication of RU94040856A publication Critical patent/RU94040856A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Abstract

Изобретение касается вакцины для перорального введения, содержащей комплекс антигенов и липида, причем липид представляет собой гликолипид, имеющий остаток маннозы, и/или фосфолипид, являющийся фосфатидилсерином. Эта пероральная вакцина способна эффективно продуцировать антитела к содержащимся в ней антигенам после перорального введения ее в живые организмы. Следовательно, теперь можно получать пероральную вакцину, содержащую микробные антигены или ослабленные микроорганизмы, которые не могли абсорбироваться при пероральном введении вакцины и которые не могли продуцировать антитела к антигенам в предыдущей практике.

Claims (1)

  1. Изобретение касается вакцины для перорального введения, содержащей комплекс антигенов и липида, причем липид представляет собой гликолипид, имеющий остаток маннозы, и/или фосфолипид, являющийся фосфатидилсерином. Эта пероральная вакцина способна эффективно продуцировать антитела к содержащимся в ней антигенам после перорального введения ее в живые организмы. Следовательно, теперь можно получать пероральную вакцину, содержащую микробные антигены или ослабленные микроорганизмы, которые не могли абсорбироваться при пероральном введении вакцины и которые не могли продуцировать антитела к антигенам в предыдущей практике.
RU94040856/14A 1992-03-03 1993-03-02 Вакцина для перорального введения RU94040856A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4552892 1992-03-03
JP45528/1992 1992-03-03

Publications (1)

Publication Number Publication Date
RU94040856A true RU94040856A (ru) 1996-08-20

Family

ID=12721912

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94040856/14A RU94040856A (ru) 1992-03-03 1993-03-02 Вакцина для перорального введения

Country Status (6)

Country Link
EP (1) EP0640347A1 (ru)
KR (1) KR950700083A (ru)
CA (1) CA2131442A1 (ru)
FI (1) FI944052A (ru)
RU (1) RU94040856A (ru)
WO (1) WO1993017702A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668934B2 (en) * 1992-04-10 1996-05-23 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
JP4033497B2 (ja) 1996-09-06 2008-01-16 三菱化学株式会社 ワクチン製剤
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6669679B1 (en) 2000-01-07 2003-12-30 Acist Medical Systems, Inc. Anti-recoil catheter
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
GB0426481D0 (en) 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
AU2008307042B2 (en) * 2007-10-03 2014-01-30 Immunovaccine Technologies Inc. Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US9028797B2 (en) 2010-02-26 2015-05-12 Nagasaki University Composite body for antigen or drug delivery
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013137854A1 (en) * 2012-03-12 2013-09-19 Empire Technology Development Llc Antibodies that bind to nanoparticles
FR3119325B1 (fr) * 2021-01-29 2023-08-11 Renault Jean Yves Compositions liposomales orales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564500A (en) * 1975-09-29 1980-04-10 Wellcome Found Biological preparations
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
CA1256372A (en) * 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
JPS63107742A (ja) * 1986-05-20 1988-05-12 Wako Pure Chem Ind Ltd 新規な機能性リポソ−ム及びその製造法
JP2641472B2 (ja) * 1988-01-30 1997-08-13 日本レダリー株式会社 感染症治療剤
WO1989008499A1 (en) * 1988-03-17 1989-09-21 Nippon Fine Chemical Co., Ltd. Liposome

Also Published As

Publication number Publication date
EP0640347A1 (en) 1995-03-01
CA2131442A1 (en) 1993-09-04
WO1993017702A1 (en) 1993-09-16
KR950700083A (ko) 1995-01-16
FI944052A0 (fi) 1994-09-02
FI944052A (fi) 1994-09-02

Similar Documents

Publication Publication Date Title
RU94040856A (ru) Вакцина для перорального введения
RU94042386A (ru) Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита
RU94028670A (ru) Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
AR077474A2 (es) El uso de un anticuerpo anti tnf alfa neutralizador de alta afinidad, en la fabricacion de un medicamento y conjunto de elementos
FI922151A (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
RU95113862A (ru) Производные пирролопиримидинов, фармацевтическая композиция, промежуточные соединения
SE8300736D0 (sv) Novel pharmacologically active compounds
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
GR78462B (ru)
AU4951196A (en) Vaccines for plague
NO981963D0 (no) Influensavaksine-blandinger
PL307914A1 (en) Lipopetide derivatives, method of obtaining them and therapeutic agents containing such compounds
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US4203971A (en) Neisseria gonorrhoeae vaccine
KR920703111A (ko) 테크네튬으로 1가의 항체단편을 빠르게 방사성라벨링하는 방법
AU611113B2 (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
SE8702734L (sv) Monoklonala antikroppar mot pseudomonas aeruginosa-flageller
Weber et al. Differential modulation of the effects of lipopolysaccharide on macrophages by a major outer membrane protein of Proteus mirabilis.
RU94019991A (ru) Антибиотическая композиция
ATE24398T1 (de) Arzneimittelformulierung zur oralen verabreichung mit gehalt an einem glycosid antibiotikum und einem hilfsstoff.